IP Library › Granted Patent US 8,617,577
Granted Patent B2
US 8,617,577 · App. 13/764,543 · Granted Dec 31, 2013

Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications

Inventors: Steven Crain (State College, PA); William E. Crain (Pownal, ME); Stanley M. Crain (State College, PA); Michael Crain (Essex, CT)
Assignee: Pondera Biotechnologies Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,577
App. No.
13/764,543
Granted
Dec 31, 2013
Kind
B2
Abstract

The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.

Claims (11)

1. A method to safely and effectively treat asthma or chronic obstructive pulmonary disease in a subject in need comprising:

(a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone in an amount of about 1 microgram to about 500 micrograms; and

(b) administering an Endorphin Enhancer, wherein the Endorphin Enhancer is selected from the group consisting of theophylline, roflumilast, ibudilast, cilomilast, zaprinast, rolipram, methylxanthine.

2. The method of claim 1 , wherein the method results in improving respiration.

3. The method of claim 1 , wherein the combination of the Receptor Switcher with the Endorphin Enhancer results in a decrease in side effects associated with administration of the compounds alone.

4. The method of claim 1 , wherein the Receptor Switcher, when co-administered with the Endorphin Enhancer, reduces and/or resolves one or more symptoms of asthma or chronic obstructive pulmonary disease.

5. The method of claim 1 , wherein the subject has previously taken an Endorphin Enhancer, an Exogenous Opioid, a Synergistic Enhancer, or any combination thereof.

6. The method of claim 1 , wherein:

(a) the mode of administration is oral;

(b) the pharmaceutical formulation is delivered in a pharmaceutically-acceptable carrier that is rapid release, immediate-release, slow-release, delayed-released, controlled release, a combination of immediate release and controlled release, a nano-encapsulation formulations, and an abuse and/or tamper-resistant delivery system;

or (c) any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2013
From: CRAIN, STEVEN; CRAIN, WILLIAM E.; CRAIN, STANLEY M.; CRAIN, MICHAEL
To: PONDERA BIOTECHNOLOGIES INC.
Reel/Frame 031549/0837 →
Continuity (12)
Continuation 13460467 · Apr 30, 2012
Continuation 12973839 · Dec 20, 2010
Provisional Application 61289293 · Dec 22, 2009
Provisional Application 61309766 · Mar 2, 2010
Provisional Application 61322665 · Apr 9, 2010
Provisional Application 61323465 · Apr 13, 2010
Provisional Application 61330631 · May 3, 2010
Provisional Application 61351653 · Jun 4, 2010
Provisional Application 61375463 · Aug 20, 2010
Provisional Application 61385873 · Sep 23, 2010
Provisional Application 61386952 · Sep 27, 2010
Related Publication 20130156874A1 · Jun 20, 2013